Azilect®

DRUG4 trials

Sponsors

H. Lundbeck A/S, University Hospital, Clermont-Ferrand, Teva Pharma GmbH

Conditions

ApathyDrug-naïve Patients With Parkinson's DiseaseParkinson's Disease

Phase 3

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

CompletedNCT01268891

H. Lundbeck A/SParkinson's Disease

Start: 2011-01-31Updated: 2013-12-03

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

CompletedNCT01479530

H. Lundbeck A/SParkinson's Disease

Start: 2011-12-31End: 2013-06-30Updated: 2018-09-10

Phase 4

Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study

University Hospital, Clermont-FerrandApathy, Drug-naïve Patients With Parkinson's Disease

Start: 2013-06-30End: 2015-03-31Target: 50Updated: 2013-01-10

Unknown Phase

Azilect® In Wearing-Off (AIWO)

CompletedNCT02384512

Teva Pharma GmbHParkinson's Disease

Start: 2014-01-31End: 2015-01-31Updated: 2023-04-12

Related Papers

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China

Translational Neurodegeneration2018-06-2631 citations